AZN Q2 Earnings and Sales Beat, Key Drugs Offset Generic Pressure - Zacks Investment Research
AZN Q2 Earnings and Sales Beat, Key Drugs Offset Generic Pressure Zacks Investment Research
重要性：RSS 导入条目，等待编辑或代理补充市场影响解读。
$8000 call bet on AZN
AZN reported $2.63 eps this morning (.13 beat) and beat on revenue with just past $15 billion for the quarter. More important they reiterated guidance of $80 billion for 2030. 33% higher than 2026. They also reported a positive readout on some cancer drug with $5 billion annual potential. So I’m betting we get some upgrades tomorrow with August $155 calls. I also like sector rotation. AZN has lagged the other premier pharma companies. I’m sure someone here knows a lot more about Big Pharma than I do. Dammit. I forgot how to post the image of the trade.   submitted by   /u/fatuousfatwa [link]   [comments]
重要性：RSS 导入条目，等待编辑或代理补充市场影响解读。